Investigational Drug Information for Ulixertinib
✉ Email this page to a colleague
What is the drug development status for Ulixertinib?
Ulixertinib is an investigational drug.
There have been 10 clinical trials for Ulixertinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 12th 2015.
The most common disease conditions in clinical trials are Glioma, Neoplasms, and Lymphoma. The leading clinical trial sponsors are BioMed Valley Discoveries, Inc, National Cancer Institute (NCI), and Dana-Farber Cancer Institute.
There are eighteen US patents protecting this investigational drug and two hundred and nine international patents.
Summary for Ulixertinib
| US Patents | 18 |
| International Patents | 209 |
| US Patent Applications | 125 |
| WIPO Patent Applications | 144 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 1 (2015-08-12) |
| Vendors | 50 |
Recent Clinical Trials for Ulixertinib
| Title | Sponsor | Phase |
|---|---|---|
| Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults | BioMed Valley Discoveries, Inc | Phase 1 |
| Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults | M.D. Anderson Cancer Center | Phase 1 |
| Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies | BioMed Valley Discoveries, Inc | Phase 2 |
Clinical Trial Summary for Ulixertinib
Top disease conditions for Ulixertinib
Top clinical trial sponsors for Ulixertinib
US Patents for Ulixertinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ulixertinib | ⤷ Try a Trial | Compounds and compositions as inhibitors of MEK | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| Ulixertinib | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Ulixertinib | ⤷ Try a Trial | Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 | Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| Ulixertinib | ⤷ Try a Trial | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | Loxo Oncology, Inc. (Stamford, CT) Array Biopharma, Inc. (Boulder, CO) | ⤷ Try a Trial |
| Ulixertinib | ⤷ Try a Trial | Cancer treatment using combinations of ERK and RAF inhibitors | BIOMED VALLEY DISCOVERIES, INC. (Kansas City, MO) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ulixertinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ulixertinib | Argentina | AR097326 | 1989-12-31 | ⤷ Try a Trial |
| Ulixertinib | Australia | AU2014307593 | 1989-12-31 | ⤷ Try a Trial |
| Ulixertinib | Brazil | BR112016001783 | 1989-12-31 | ⤷ Try a Trial |
| Ulixertinib | Canada | CA2921300 | 1989-12-31 | ⤷ Try a Trial |
| Ulixertinib | Chile | CL2016000150 | 1989-12-31 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
